Research Topics
| D H ThammSummaryAffiliation: Colorado State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept studyD H Thamm
The Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523 1620, USA
Vet J 191:131-4. 2012..The findings justify further investigation into those combinations that may potentially yield therapeutic benefit...
Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisoneJoshua D Webster
Comparative Medicine and Integrative Biology Program, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
BMC Vet Res 4:32. 2008..Disease-free intervals (DFI) and overall survival times (OS) of dogs with similar pretreatment prognostic indices postoperatively treated with chemotherapy were compared to dogs treated with surgery alone...
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluationDouglas H Thamm
Department of Medical Sciences and Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin Madison, USA
Clin Cancer Res 11:4827-34. 2005....- Cyclooxygenase-2 expression in equine tumorsD H Thamm
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
Vet Pathol 45:825-8. 2008..There were no differences in expression between anatomic sites. In conclusion, most equine SCC and many melanomas appear to express COX-2 and thus could respond to COX-2 inhibitor therapy... - Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcomaD H Thamm
Department of Clinical Sciences, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
Vet Comp Oncol 6:126-32. 2008..These data support a role for VEGF in the development or progression of metastatic disease in dogs with OSA. The VEGF concentration in tested sera was not a major determinant of ex vivo canine EC proliferation in this study... - Biological and molecular characterization of a canine hemangiosarcoma-derived cell lineDouglas H Thamm
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 53706, USA
Res Vet Sci 81:76-86. 2006.... - RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic targetDouglas H Thamm
The Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523 1620, USA
Melanoma Res 20:35-42. 2010..In conclusion, this study suggests that similar TKs are expressed in human and canine melanoma, and shows potential antitumor effects of IGF-1R inhibition in CMM... - Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluationDouglas H Thamm
Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
Clin Cancer Res 16:1498-508. 2010..This study characterized toxicity, biological effect, and antitumor activity of PEG-TNF in pet dogs with spontaneous cancer... - Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled studyJ C Lori
Animal Cancer Center, Colorado State University College of Veterinary Medicine, Fort Collins, CO 80523 1620, USA
Vet Comp Oncol 8:188-95. 2010..Despite a numeric improvement in outcome in cyclophosphamide treated dogs, the addition of cyclophosphamide did not result in statistically improved response rate, PFI or ST... - Increased monocyte chemotactic protein-1 concentration and monocyte count independently associate with a poor prognosis in dogs with lymphomaJ A Perry
Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
Vet Comp Oncol 9:55-64. 2011..The mechanisms underlying these observations remain to be determined... - Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancerL Mitchell
Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523 1620, USA
J Vet Intern Med 26:355-62. 2012..The immunomodulatory effects of the TKI toceranib, as a single agent or in combination with metronomic CYC, have not been previously investigated in dogs... - Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcomaJ H Burton
Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, CO 80523, USA
J Vet Intern Med 25:920-6. 2011..The effects of metronomic chemotherapy on Treg and tumor angiogenesis in dogs has not been investigated previously... - Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograftJ L Sottnik
Department of Clinical Sciences, Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523, USA
Vet Comp Oncol 9:118-30. 2011..These data suggest that tepoxalin may moderately inhibit tumour growth and may be administered as an analgesic to tumour-bearing dogs... - Glucose transporter 1 expression in canine osteosarcomaJ C Petty
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523 1678, USA
Vet Comp Oncol 6:133-40. 2008..As hypothesized, GLUT-1 is present in canine appendicular OSAs. A more objective evaluation of GLUT-1 and other proteins in the HIF-1alpha pathway may be warranted... - Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumorsK S Carlsten
Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA
J Vet Intern Med 26:135-41. 2012..Mast cell tumors (MCT) are common cutaneous tumors in dogs and when not amenable to surgical excision can present a therapeutic challenge. New treatment protocols for unresectable MCT are needed... - Comparative analysis of survivin expression in untreated and relapsed canine lymphomaR B Rebhun
Department of Clinical Sciences, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
J Vet Intern Med 22:989-95. 2008..Survivin expression has been shown to be a negative prognostic factor in several cancers of humans, including B-cell non-Hodgkin's lymphoma... - Dose-escalating vinblastine for the treatment of canine mast cell tumourK R Vickery
The Animal Cancer Center, Colorado State University, Fort Collins, CO 80523 1620, USA
Vet Comp Oncol 6:111-9. 2008..Randomized prospective trials are necessary to establish whether dose escalation will translate into improved response rates when compared with the standard 2 mg m(-2) dosage... - Interleukin-11 receptor alpha is expressed on canine osteosarcomaJ L Sottnik
Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, CO, USA
Vet Comp Oncol 8:96-102. 2010..Cytotoxin-conjugated antibodies targeting IL-11Ralpha-mediated canine OSA cytotoxicity. Thus, canine OSA may be a valuable model for the evaluation of IL-11Ralpha directed therapies... - Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphomaC F Saba
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, WI, USA
J Vet Intern Med 23:1058-63. 2009..In a previous study, we reported that remission was typically lost around the time L-asparaginase was discontinued... - Impact of telomerase status on canine osteosarcoma patientsK Kow
Department of Clinical Science, Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
J Vet Intern Med 22:1366-72. 2008..The purpose of the current study was to examine the telomerase status of a large number of OSA samples from dogs and determine if telomerase status can serve as a prognostic factor... - Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcomaJ L Sottnik
Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, CO 80523, USA
J Vet Intern Med 24:1439-44. 2010..Identification of biomarkers that predict outcomes in dogs with osteosarcoma (OSA) would be valuable to veterinarians and owners. Leukocyte numbers in peripheral blood are associated with outcomes in some types of cancer in humans... - Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*D H Thamm
Animal Cancer Center, Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
Vet Comp Oncol 10:292-302. 2012..When interval thresholds of <1.55 and >7.95 U/L were used together, diagnostic utility was increased. Serum TK1 evaluation may help to discriminate between benign disease and HSA in dogs with hemoabdomen and a splenic mass... - Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 casesD H Thamm
Department of Clinical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison 53704, USA
J Vet Med Sci 68:581-7. 2006..High-grade and mucocutaneous tumors had a worse outcome, and the use of prophylactic nodal irradiation appeared to improve outcome in this group of dogs... - Pharmacokinetic modeling of doxorubicin pharmacokinetics in dogs deficient in ABCB1 drug transportersD L Gustafson
Department of Clinical Sciences, and the Animal Cancer Center, Colorado State University, Fort Collins, CO 80523 1620, USA
J Vet Intern Med 24:579-86. 2010..The identification of dogs defective in ATP-binding cassette transporter B1 (ABCB1, MDR1) activity has prompted questions regarding pharmacokinetics (PK), efficacy and toxicity of ABCB1 substrates in these dogs... - Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine modelD M Vail
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA
Clin Cancer Res 4:1567-71. 1998..We conclude that pyridoxine is effective in delaying the onset and severity of PPES in this canine model... - Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell linesK C Kennedy
The Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA
Vet Comp Oncol 9:196-206. 2011..In conclusion, EGF stimulates multiple features promoting the malignant phenotype in CMT. Thus, CMT may be an important translational model for the investigation of novel EGFR-directed therapies... - Lung tumor development and spontaneous regression in lambs coinfected with Jaagsiekte sheep retrovirus and ovine lentivirusS F Hudachek
Animal Cancer Center, Veterinary Teaching Hospital, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523 1620, USA
Vet Pathol 47:148-62. 2010..Overall, the genetic profile combined with the disease development data provides further important characterization of OPA and describes, for the first time, spontaneous regression of OPA tumors in experimentally infected sheep... - Phase II clinical evaluation of lomustine chemotherapy for feline vaccine-associated sarcomaC F Saba
Departments of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA
Vet Comp Oncol 10:283-91. 2012..Although these data support further investigation of lomustine for the treatment of VAS, safe, multidosing protocols must first be determined... - Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumorsDouglas H Thamm
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Drive West, WI 53706, Madison, USA
Cancer Immunol Immunother 52:473-80. 2003..In conclusion, these studies suggests that intralesional L-SEA/cIL-2 immunotherapy is well tolerated, results in detectable transgene expression in canine tumors, and has antitumor activity in dogs with spontaneous STS... - Preclinical study of dolastatin-10 in dogs with spontaneous neoplasiaDouglas H Thamm
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, 2015 Linden Drive West, Madison, WI 53706, USA
Cancer Chemother Pharmacol 49:251-5. 2002..To evaluate the short-term adverse effects of administration of dolastatin-10 (Dol-10) to dogs with spontaneously occurring malignant tumors... - c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cellsE Gregory MacEwen
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
Clin Exp Metastasis 20:421-30. 2003..These data support the involvement of c-Met and HGF-SF in the growth and progression of human and canine OS, and may offer new targets for the development of therapeutic strategies for OS... - Evaluation of a novel tumor vaccine in dogs with hemangiosarcomaBarbara J Biller
Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins 80523, USA
J Vet Intern Med 21:113-20. 2007..Therefore, we evaluated safety and immunologic responses to a novel tumor vaccine administered together with doxorubicin chemotherapy in dogs with different stages of HSA... - Systems biology approach to identification of biomarkers for metastatic progression in cancerAndrey A Ptitsyn
Center for Bioinformatics, Department of Microbiology, Immunology and Pathology, Colorado State University, Colorado, USA
BMC Bioinformatics 9:S8. 2008..Previous studies of gene expression patterns in metastasis have concentrated on selection of a small number of "signature" biomarkers... - Aftershocks of cancer chemotherapy: managing adverse effectsDouglas H Thamm
The Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
J Am Anim Hosp Assoc 43:1-7. 2007..This article presents guidelines for the management of chemotherapy-associated hematological and gastrointestinal disturbances, extravasation injury, and anaphylaxis... - Successful treatment of acute tumor lysis syndrome in a dog with multicentric lymphomaKathryn R Vickery
Animal Cancer Center, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523-1620, USA
J Vet Intern Med 21:1401-4. 2007 - Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphomaLaura D Garrett
Kansas State University Veterinary Medical Teaching Hospital, USA
J Vet Intern Med 16:704-9. 2002..4% (5/53) needing hospitalization. The 6-month chemotherapy protocol based on CHOP with no maintenance phase provides similar DFI and survival times when compared to a similar protocol with a prolonged maintenance phase... - Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004)Marie N Mullins
Animal Cancer Center and Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
J Am Vet Med Assoc 228:91-5. 2006..CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that multiple cutaneous MCTs in dogs are associated with a low rate of metastasis and a good prognosis for long-term survival with adequate excision of all MCTs... - Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985-1995)Laurel E Williams
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA
J Am Vet Med Assoc 223:825-31. 2003..To characterize the signalment, clinical signs, biological behavior, and response to treatment of carcinoma of the apocrine glands of the anal sac in dogs... - IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcomaE Gregory MacEwen
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
J Cell Biochem 92:77-91. 2004..There is suggestive evidence that increasing receptor number may contribute to in vivo tumorigenesis. Additional studies are needed to determine how IGF-1/IGF-1R interactions contribute to the malignant phenotype of OS... - Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphomaCorey F Saba
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison 53706, USA
J Vet Intern Med 21:127-32. 2007..Canine lymphoma (LSA) is responsive to initial treatment, however, it then becomes resistant to drugs in the initial protocol. New rescue protocols are needed... - Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcomaRieko Katayama
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, WI 53706, USA
Cancer Chemother Pharmacol 54:25-33. 2004..These observations suggest that imatinib inhibits PDGFR tyrosine kinase activity in feline soft tissue sarcomas in vitro and inhibits tumor growth in a xenograft model... - Plasma synthesis of carbon magnetic nanoparticles and immobilization of doxorubicin for targeted drug deliveryYonghui Ma
Center for Plasma-Aided Manufacturing, University of Wisconsin, Madison, WI 53706, USA
J Biomater Sci Polym Ed 15:1033-49. 2004..The in vitro antiproliferative activity of immobilized doxorubicin in the conjugates was demonstrated in tumor cell cytotoxicity assays. It is suggested that this CMNP-DOX system can be used for targeted drug-delivery systems... - Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?Valerie S MacDonald
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin Madison, Madison, WI, USA
J Vet Intern Med 19:732-6. 2005..Therefore, it may be more appropriate to reserve the use of L-ASP for treating relapse in dogs with lymphoma that have failed induction therapy... - Cytotoxic chemotherapy: new players, new tacticsDavid M Vail
Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523, USA
J Am Anim Hosp Assoc 41:209-14. 2005..This article describes the drug development process and how a new product eventually finds its way into clinical use. Some of the newer drugs and delivery techniques applied to small animals are reviewed... - GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphomaHans Reiser
Department of Research and Development, Gilead Sciences, Inc, Foster City, California 94404, USA
Clin Cancer Res 14:2824-32. 2008..Our objective was to characterize the antiproliferative activity, pharmacokinetics, pharmacodynamics, and safety of GS-9219...